Limits...
Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis.

Li Y, Shi B, Li S - PLoS ONE (2014)

Bottom Line: For each variable, summary correlation coefficients were estimated using random-effects or fixed-effect meta-analysis with 95% confidence interval (CI) performed by STATA software.The meta-analyse of diabetes markers showed that FSI (rs = 0.26; 95% CI = 0.21-0.31; P = 0.000), 2HPG (rs = 0.06; 95% CI = 0.01-0.12; P = 0.030) and HOMA-IR (rs = 0.178; 95% CI = 0.019-0.337; P = 0.028) were positively correlated with chemerin, however, FPG (rs = 0.03, 95% CI = -0.02 to 0.08, P = 0.240) and HbA1c (rs = -0.05; 95% CI = -0.24-0.15; P = 0.641) were not significantly correlated with chemerin.Sensitivity analysis was performed and the summary results did not change significantly.

View Article: PubMed Central - PubMed

Affiliation: Department of endocrinology, The First Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710061, China; Department of endocrinology, Yan'an University Affiliated Hospital, Yan'an 716000, China.

ABSTRACT

Objective: Chemerin is a novel adipokine. Previous research has investigated the association between chemerin and clinical indices in patients with obesity or metabolic syndrome (MS), although the results obtained have been inconsistent. We conducted a meta-analysis to investigate the association between chemerin and clinical indicators of diabetes, MS and obesity with obesity or MS subjects.

Design and methods: Studies were identified by searching the PubMed, the Cochrane Library, EMBASE and CNKI, databases beginning with the original report in July 2007 until the end of May 2013. For each variable, summary correlation coefficients were estimated using random-effects or fixed-effect meta-analysis with 95% confidence interval (CI) performed by STATA software.

Results: A total of eight studies with 20 clinical variables (total n = 1787) met the inclusion criteria. The meta-analyse of diabetes markers showed that FSI (rs = 0.26; 95% CI = 0.21-0.31; P = 0.000), 2HPG (rs = 0.06; 95% CI = 0.01-0.12; P = 0.030) and HOMA-IR (rs = 0.178; 95% CI = 0.019-0.337; P = 0.028) were positively correlated with chemerin, however, FPG (rs = 0.03, 95% CI = -0.02 to 0.08, P = 0.240) and HbA1c (rs = -0.05; 95% CI = -0.24-0.15; P = 0.641) were not significantly correlated with chemerin. The meta-analyses of MS and obesity markers indicated that TG, TC, CRP BMI, TBF%, WC, WHR and Leptin were positively correlated with chemerin, nevertheless, SBP, DBP, LDL-C, HDL-C, ALT and r-GT were not significantly correlated, adiponectin was negatively correlated. Sensitivity analysis was performed and the summary results did not change significantly.

Conclusions: The results suggest that chemerin in patients with obesity or MS may be associated with obesity, imbalances in lipid and diabetes metabolism and insulin resistance. Chemerin played an important role in the pathophysiology of obesity and MS.

Show MeSH

Related in: MedlinePlus

Correlations between serum chemerin concentrations and diabetes markers in Obesity or MS subjects.Summaries are shown of the correlations between serum chemerin concentrations and (a) fasting plasma glucose concentrations, (b) fasting serum insulin concentrations, (c) 2H postprandial plasma glucose, (d) HOMA_IR and (e) Hemoglobin A1c. 95% confidence intervals (CIs) are represented by the horizontal lines, and diamonds represent the overall estimate and 95% CI.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4254750&req=5

pone-0113915-g002: Correlations between serum chemerin concentrations and diabetes markers in Obesity or MS subjects.Summaries are shown of the correlations between serum chemerin concentrations and (a) fasting plasma glucose concentrations, (b) fasting serum insulin concentrations, (c) 2H postprandial plasma glucose, (d) HOMA_IR and (e) Hemoglobin A1c. 95% confidence intervals (CIs) are represented by the horizontal lines, and diamonds represent the overall estimate and 95% CI.

Mentions: Six of the studies presented data on the association between FPG and chemerin concentrations in patients with obesity or MS (total n = 1439; Fig. 2a) [4], [9], [13]–[16]. Fig. 2a (using fixed-effects model) showed these five markers were not significantly correlated with serum chemerin concentrations, nor was the overall correlation coefficient statistically significant (rs = 0.03, 95% CI–0.02 to 0.08, P = 0.240). Six researches examined the association between FSI and serum chemerin concentrations in patients with obesity or MS (total n = 1439; Fig. 2b) [4], [9], [13]–[16]. Four studies investigated the association between 2HPG and serum chemerin concentrations (total n = 1222; Fig. 2c) [4], [9], [14], [15]. Eventually, FSI (rs = 0.26; 95% CI = 0.21–0.31; P = 0.000) and 2HPG (rs = 0.06; 95% CI = 0.01–0.12; P = 0.030) were positively correlated with serum chemerin concentrations. Seven studies examined the association between HOMA-IR and serum chemerin concentrations (total n = 1484; Fig. 2d) [4], [9], [13]–[17]. The Fig. 2d (using random-effects model) suggested that HOMA-IR was positively correlated with serum chemerin concentrations (rs = 0.178; 95% CI = 0.019–0.337; P = 0.028). Based on sensitivity analysis, the study on the maximum of heterogeneity was excluded [9]; HOMA-IR resulted in a summary coefficient of 0.233 (95% CI = 0.126 to 0.341; P = 0.000). Two researches investigated the association between HbA1c and serum chemerin concentrations (total n = 1222; Fig. 2e) [14], [15]. On the whole, HbA1c was not correlated with serum chemerin concentrations (rs = −0.05; 95% CI = −0.24–0.15; P = 0.641).


Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis.

Li Y, Shi B, Li S - PLoS ONE (2014)

Correlations between serum chemerin concentrations and diabetes markers in Obesity or MS subjects.Summaries are shown of the correlations between serum chemerin concentrations and (a) fasting plasma glucose concentrations, (b) fasting serum insulin concentrations, (c) 2H postprandial plasma glucose, (d) HOMA_IR and (e) Hemoglobin A1c. 95% confidence intervals (CIs) are represented by the horizontal lines, and diamonds represent the overall estimate and 95% CI.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4254750&req=5

pone-0113915-g002: Correlations between serum chemerin concentrations and diabetes markers in Obesity or MS subjects.Summaries are shown of the correlations between serum chemerin concentrations and (a) fasting plasma glucose concentrations, (b) fasting serum insulin concentrations, (c) 2H postprandial plasma glucose, (d) HOMA_IR and (e) Hemoglobin A1c. 95% confidence intervals (CIs) are represented by the horizontal lines, and diamonds represent the overall estimate and 95% CI.
Mentions: Six of the studies presented data on the association between FPG and chemerin concentrations in patients with obesity or MS (total n = 1439; Fig. 2a) [4], [9], [13]–[16]. Fig. 2a (using fixed-effects model) showed these five markers were not significantly correlated with serum chemerin concentrations, nor was the overall correlation coefficient statistically significant (rs = 0.03, 95% CI–0.02 to 0.08, P = 0.240). Six researches examined the association between FSI and serum chemerin concentrations in patients with obesity or MS (total n = 1439; Fig. 2b) [4], [9], [13]–[16]. Four studies investigated the association between 2HPG and serum chemerin concentrations (total n = 1222; Fig. 2c) [4], [9], [14], [15]. Eventually, FSI (rs = 0.26; 95% CI = 0.21–0.31; P = 0.000) and 2HPG (rs = 0.06; 95% CI = 0.01–0.12; P = 0.030) were positively correlated with serum chemerin concentrations. Seven studies examined the association between HOMA-IR and serum chemerin concentrations (total n = 1484; Fig. 2d) [4], [9], [13]–[17]. The Fig. 2d (using random-effects model) suggested that HOMA-IR was positively correlated with serum chemerin concentrations (rs = 0.178; 95% CI = 0.019–0.337; P = 0.028). Based on sensitivity analysis, the study on the maximum of heterogeneity was excluded [9]; HOMA-IR resulted in a summary coefficient of 0.233 (95% CI = 0.126 to 0.341; P = 0.000). Two researches investigated the association between HbA1c and serum chemerin concentrations (total n = 1222; Fig. 2e) [14], [15]. On the whole, HbA1c was not correlated with serum chemerin concentrations (rs = −0.05; 95% CI = −0.24–0.15; P = 0.641).

Bottom Line: For each variable, summary correlation coefficients were estimated using random-effects or fixed-effect meta-analysis with 95% confidence interval (CI) performed by STATA software.The meta-analyse of diabetes markers showed that FSI (rs = 0.26; 95% CI = 0.21-0.31; P = 0.000), 2HPG (rs = 0.06; 95% CI = 0.01-0.12; P = 0.030) and HOMA-IR (rs = 0.178; 95% CI = 0.019-0.337; P = 0.028) were positively correlated with chemerin, however, FPG (rs = 0.03, 95% CI = -0.02 to 0.08, P = 0.240) and HbA1c (rs = -0.05; 95% CI = -0.24-0.15; P = 0.641) were not significantly correlated with chemerin.Sensitivity analysis was performed and the summary results did not change significantly.

View Article: PubMed Central - PubMed

Affiliation: Department of endocrinology, The First Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710061, China; Department of endocrinology, Yan'an University Affiliated Hospital, Yan'an 716000, China.

ABSTRACT

Objective: Chemerin is a novel adipokine. Previous research has investigated the association between chemerin and clinical indices in patients with obesity or metabolic syndrome (MS), although the results obtained have been inconsistent. We conducted a meta-analysis to investigate the association between chemerin and clinical indicators of diabetes, MS and obesity with obesity or MS subjects.

Design and methods: Studies were identified by searching the PubMed, the Cochrane Library, EMBASE and CNKI, databases beginning with the original report in July 2007 until the end of May 2013. For each variable, summary correlation coefficients were estimated using random-effects or fixed-effect meta-analysis with 95% confidence interval (CI) performed by STATA software.

Results: A total of eight studies with 20 clinical variables (total n = 1787) met the inclusion criteria. The meta-analyse of diabetes markers showed that FSI (rs = 0.26; 95% CI = 0.21-0.31; P = 0.000), 2HPG (rs = 0.06; 95% CI = 0.01-0.12; P = 0.030) and HOMA-IR (rs = 0.178; 95% CI = 0.019-0.337; P = 0.028) were positively correlated with chemerin, however, FPG (rs = 0.03, 95% CI = -0.02 to 0.08, P = 0.240) and HbA1c (rs = -0.05; 95% CI = -0.24-0.15; P = 0.641) were not significantly correlated with chemerin. The meta-analyses of MS and obesity markers indicated that TG, TC, CRP BMI, TBF%, WC, WHR and Leptin were positively correlated with chemerin, nevertheless, SBP, DBP, LDL-C, HDL-C, ALT and r-GT were not significantly correlated, adiponectin was negatively correlated. Sensitivity analysis was performed and the summary results did not change significantly.

Conclusions: The results suggest that chemerin in patients with obesity or MS may be associated with obesity, imbalances in lipid and diabetes metabolism and insulin resistance. Chemerin played an important role in the pathophysiology of obesity and MS.

Show MeSH
Related in: MedlinePlus